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Abstract
Background: The Brazilian Study on the Practice of Diabetes Care main objective was to provide an
epidemiological profile of individuals with type 1 and 2 diabetes mellitus (DM) in Brazil, concerning therapy and
adherence to international guidelines in the medical practice.
Methods: This observational, cross-sectional, multicenter study collected and analyzed data from individuals with
type 1 and 2 DM attending public or private clinics in Brazil. Each investigator included the first 10 patients with
type 2 DM who visited his/her office, and the first 5 patients with type 1 DM.
Results: A total of 1,358 patients were analyzed; 375 (27.6%) had type 1 and 983 (72.4%) had type 2 DM. Most
individuals were women, Caucasian, and private health care users. High prevalence rates of hypertension,
dyslipidemia and central obesity were observed, particularly in type 2 DM. Only 7.3% and 5.1% of the individuals
with types 1 and 2 DM, respectively, had optimal control of blood pressure, plasma glucose and lipids. The absence
of hypertension and female sex were associated with better control of type 1 DM and other cardiovascular risk
factors. In type 2 DM, older age was also associated with better control.
Conclusions: Female sex, older age, and absence of hypertension were associated with better metabolic control.
An optimal control of plasma glucose and other cardiovascular risk factors are obtained only in a minority of
individuals with diabetes. Local numbers, compared to those from other countries are worse.
Keywords: Diabetes mellitus, Risk factors, Cardiovascular disease
Introduction
The prevalence of diabetes mellitus (DM) is increasing
worldwide, associated with the aging population and the
epidemiological transition [1]. Concomitant with the de-
velopment of human societies which caused significant
reductions in mortality related to infectious diseases, the
adoption of a inadequate lifestyle with less physical activity
and higher consumption of sugar and fat transformed
obesity in a epidemic, which poses as a risk for the devel-
opment of DM [2]. It is estimated that by 2030, 366 mil-
lion individuals will be affected by the disease worldwide,
being 11.3 million living in Brazil where this would
represent an increase of almost three times the number of
individuals with the disease today [3].
DM is currently the fifth leading cause of mortality
worldwide by increasing the risk of cardiovascular dis-
ease when compared to populations without diabetes
[4,5]. Besides that, microvascular complications markedly
deteriorate their quality of life. Tight plasma glucose con-
trol, either with the use of insulin or oral glucose lowering
agents, and the control of other cardiovascular risk factors,
such as hypertension and dyslipidemia, are recommended
nowadays in order to reduce morbidity and mortality asso-
ciated with DM [6-14]. In addition to correcting glycemia,
the combination of medications such as statins, anti-
platelet agents and angiotensin-converting enzymes inhibi-
tors is crucial in the treatment of patients affected by the
disease.* Correspondence: avezum@yahoo.com2Divisão de Pesquisa, Instituto Dante Pazzanese de Cardiologia, São Paulo,
São Paulo, Brazil
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Despite the evidence from relevant clinical trials, sev-
eral studies conducted in Western countries have indi-
cated a large gap between what is recommended and
actually done in daily clinical practice [15-18]. The mere
knowledge about efficacy of interventions does not revert
in changes in clinical practice and combined efforts to im-
prove patient care are required [19-21]. A initial step for
the implementation of scientific knowledge involves an as-
sessment of the current situation.
In Brazil, limited data regarding therapy and control of
individuals with DM, as well as the frequencies of long-
term complications and socioeconomic impact of the
disease are available. The Brazilian Study on Practices of
Diabetes Care (BDMPS) was designed to evaluate the ther-
apy of type 1 and type 2 DM in the daily medical practice
and how patients with diabetes are achieving the inter-
national recommendations for the control of plasma glu-
cose and other cardiovascular risk factors.
The objective of the present study was to describe data
of individuals with type 1 and type 2 DM, collected by the
BDMPS in a standardized way, to provide an epidemio-
logical profile of patients with diabetes mellitus in Brazil,
concerning therapy and attendance to international guide-
lines in the medical practice.
Methods
Study design
The BDMPS is a cross-sectional, multicenter study,
which collected and analyzed data from individuals with
types 1 and 2 DM living in 3 out of 5 Brazilian regions.
Study objectives
The primary objective was to evaluate the proportion of
individuals with DM in Brazil with adequate control of
glycated haemoglobin levels and other associated cardio-
vascular risk factors. The secondary objectives were to
determine the factors associated to an adequate metabolic
control; determine the therapy of patients with type 1 and 2
DM; evaluate the presence of comorbidities; and assess the
impact of diabetes on hospitalizations and employment.
Study population
Patients included were men and women, aged 18 years
old and over, diagnosed with type 1 or 2 DM, accepting to
participate in the study while visiting their doctor during
the recruitment period. Those who were already enrolled
in other clinical studies or who were on temporary use of
insulin, such as for gestational diabetes, were excluded.
Study procedures
Doctors with prior experience with insulin administration
were selected at the discretion of the sponsor. They were
trained before enrolling patients about the study proce-
dures and application of the standardized questionnaires.
Throughout two weeks, each investigator included con-
secutively in the study, the first 10 patients with type 2
DM who visited his/her office, as well as the first 5 pa-
tients with type 1 DM.
During the inclusion visit, patients were questioned and
evaluated for demographic profile, socioeconomic and cul-
tural level, history of DM, associated cardiovascular risk
factors, medications in use, laboratory measurements, out-
patient services, screening for cardiovascular diseases, and
hospitalization due to DM and its complications.
No test was performed specifically for the present study.
Investigators relied on exams which have been ordered
previously and were available for each patient according
to their own clinical practice.
Definitions
Hypertension was defined as a blood pressure ≥130/80
mmHg; dyslipidemia as LDL-cholesterol ≥100 mg/dL or
HDL-cholesterol <40 mg/dL for men and <50 mg/dL for
women or triglycerides ≥150 mg/dL; central obesity as waist
circumference >90 cm in men and >80 cm in women. Ad-
equate glycemic control was defined as a glycated haemo-
globin ≤7%.
The outcome for the multivariable logistic regression
model was the binary outcome “adequate metabolic con-
trol”. A patient was considered to be under adequate meta-
bolic control when at least 5 of the following 8 variables
were present: HbA1c ≤7%; blood pressure <130/80 mmHg;
LDL-cholesterol <100 mg/dL; triglycerides <150 mg/dL;
HDL ≥40 mg/dL for men or ≥50 mg/dL for women; ab-
dominal circumference <80 cm in women or <90 cm in
men; body mass index <25 kg/m2; and a never smoker.
Statistical considerations
The sample size was calculated based on the objective
of determining the utilization of insulin in patients with
type 2 DM. Estimating the proportion of type 2 DM in-
dividuals in use of insulin equal to 17.5%, and consider-
ing an accuracy of 2% and a confidence interval of 95%,
a sample of 1,385 participants would be necessary.
Data were expressed as means and standard deviations
or the absolute number and percentages. The independent
variables age, sex, level of education, human development
index (HDI) and hypertension were chosen a priori based
on clinical judgment as being associated with an adequate
metabolic control. These variables were assessed in a mul-
tivariable logistic regression model and the results were
expressed as adjusted odds ratios (OR) and 95% confidence
intervals (CI). Age and HDI were treated as continuous
variables and sex, level of education, and a diagnosis of
hypertension as binary variables.
A P value <0.05 was considered to be significant for all
tests. Statistical analysis was conducted using SAS statis-
tical software (version 8.02) by the company Statistika
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Consultoria. This company was retained by the study
sponsor. The sponsor submitted to monitoring ten per-
cent of the total data obtained during the investigation,
choosing randomly the investigators to be evaluated.
Ethical considerations
All investigators obtained approval from their respective
Research Ethics Committees. All participants signed the
informed consent form before participation. There was no
interference from the sponsor in the selection of the infor-
mation to be used in the preparation of this manuscript.
Results
Characteristics of investigators
A total of 107 investigators from 3 out of 5 Brazilians re-
gions participated in the study, 75 (70%) of which were
endocrinologists. The average age of the investigators was
48 years, and the average time of professional practice was
23 years. The average number of patients seen each month
by the investigators was 310 patients. Out of the 107 phy-
sicians, 71 (66.7%) attended mostly private patients.
Characteristics of patients
A total of 1,430 individuals with DM were selected be-
tween June 1, 2007 and August 18, 2007, although only
1,358 were analyzed. The other 72 patients were excluded
for not meeting the selection requirements or due to the
absence of relevant data for qualifying (age below 18 years
old, concomitant participation in a clinical trial, current
temporary use of insulin, missing data about the type of
DM, insulin use, and oral medications). Out of the 1,358
patients included in this analysis, 375 (27.6%) had type 1
DM and 983 (72.4%) had type 2 DM.
Table 1 shows the characteristics of the patients in-
cluded according to the type of DM. As expected, indi-
viduals with type 1 DM were younger than those with
type 2 DM. In both groups, there was a predominance of
women, Caucasians, and private health care users. One
third of the patients with type 2 DM and more than half
of those with type 1 DM had post-secondary education.
In the previous 3 months before the baseline visit,
9.1% of type 1 DM patients and 4.5% of type 2 DM ones
had been admitted to a hospital. In relation to the com-
plications associated with DM, nearly 40% of individuals
with type 2 DM were on sick leave, along with almost
20% of those with type 1 DM.
Treatment characteristics
Eighty-four percent of patients with type 2 DM were in
use of a glucose-lowering drug; 45% were is use of at least
2 drugs. The use of angiotensin-converting enzyme inhibi-
tors and angiotensin receptor blockers, antiplatelet agents,
and statins were 22.7% and 59.2%; 17.6% and 47.3%; 18.1%
and 48.6% in type 1 and type 2 DM, respectively.
Complications associated with diabetes
Table 1 includes the frequency of micro and macrovas-
cular complications associated with diabetes. Prior acute
coronary syndrome was reported in 1.8% and 10.4% of the
type 1 and 2 DM, respectively, and cerebrovascular acci-
dent in 1% and 4.2%.
Associated cardiovascular risk factors
Hypertension, dyslipidemia, and central obesity were pres-
ent in 23%, 28.5%, and 39% of type 1 DM and 75.7%, 71%,
and 84% of type 2 DM patients (Table 2). Table 3 shows
the proportion of patients with adequate control of blood
glucose and other cardiovascular risk factors. Adequate
glycemic control of at least 5 cardiovascular risk factors
was found in 35.7% of type 1 and 14.4% in patients with
type 2 diabetes. Only 16.7% of the individuals with type 2
DM had blood pressure below 130/80mm Hg, and around
40% had the LDL-cholesterol under 100 mg/dL (Table 3).
The multivariable logistic regression analysis showed
that female gender and absence of hypertension were in-
dependently associated with adequate control of cardio-
vascular risk factors in type 1 DM. In type 2 DM, in
addition to those variables, older age was also associated
with adequate metabolic control (Table 4).
Discussion
Physicians who participated in this study were above the
national average age, which is made up of almost 65%
under the age of 40 years. Furthermore, almost half the
practicing doctors in Brazil graduated less than 15 years
ago. Also, the specialist title in endocrinology by the major-
ity of investigators suggests that the participating doctors
should have a good experience in the medical practice [22].
Many studies have demonstrated a linear association
between the levels of glycated haemoglobin (HbA1c) and
micro and macrovascular complications - the higher the
blood glucose levels over time, the greater the association
with the development of changes associated with DM [23].
Conversely, intensive control of blood glucose levels,
and the achievement of reductions in the levels of glycated
haemoglobin prevents macro and microvascular compli-
cations in type 1 and type 2 DM [24].
However, our data shows that most patients do not
reach adequate glycemic control. Twenty-two percent
and 43.2% of those individuals with type 1 and 2 DM
had HbA1c below 7%, respectively. In a previous survey
of 6,671 patients with diabetes from public hospitals in
Brazil, the prevalence of inadequate glycemic control
(HbA1c ≥7.0%) was 76% [25]. According to the type of
DM, inadequate glycemic control was identified in 90%
of type 1 and in 73% of type 2 DM [25]. This difference
in the numbers suggests that the type of health care
(public versus private care) may have important conse-
quences over metabolic control.
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The individuals studied, especially those with type 2
DM, had a high prevalence of other cardiovascular risk
factors, such as hypertension, dyslipidemia, and central
obesity, under inadequate control.
A study analyzing the results from the National Health
and Nutrition Examination Survey (NHANES) showed
that the Brazilian figures are way inferior than those found
in the United States. In the American study, 36% of the in-
dividuals examined had blood pressure below 130/80mm
Hg, and 7.3% had optimal control of hypertension, dys-
lipidemia and glucose [17]. In a similar study conducted in
France, 37% of patients with type 2 DM had blood pressure
below 130/80mm Hg, and 28% had adequate control of
plasma lipids [18].
Our study has some strength. First, we considered not
only the glycemic control but also other metabolic abnor-
malities responsible to the increased cardiovascular risk
Table 1 Characteristics of patients included
Variables Diabetes
Type 1
(N=375)
Type 2
(N=983)
Demographics
Age – yrs 34 ± 13.2 63 ± 11.3
Female gender 232 (61.9) 535 (55)
Caucasian 246 (65.6) 595 (61.1)
BMI – kg/m2 24 ± 3.7 29 ± 5.3
25-30 16 (4.3) 255 (26.5)
30-35 4 (1.1) 119 (12.4)
>35 12 (3.2) 3 (0.3)
Waist circumference, male, cm 86 ± 11.4 102 ± 12.8
Waist circumference, female, cm 80 ± 11.9 96 ± 13.8
Socioeconomic profile
University level or higher 201 (53.7) 321 (33.5)
Private health insurance 310 (82.7) 833 (85.1)
Full/part time employment 263 (70.7) 381 (38.9)
Sick leave if employed* 26 (6.9) 21 (2.1)
Unemployment related to disability 67 (17.8) 364 (37)
Laboratorial measurements
Fasting plasma glucose – mg/dL 151 ± 81.7 143 ± 57.2
Glycated hemoglobin – % 8.4 ± 1.9 7.5 ± 1.6
Total cholesterol – mg/dL 179 ± 45.2 181 ± 41.6
LDL-cholesterol – mg/dL 102 ± 33.5 102 ± 39.2
HDL-cholesterol – mg/dL 58 ± 41.2 48 ± 22.5
Triglycerides – mg/dL 103 ±74.9 157 ± 105
Time since diagnosis – yrs 16 ± 10.8 11 ± 8.7
Medications
Use of glucose-lowering drug 43 (11.5) 827 (84.1)
Metformin 31 (8.3) 270 (27.5)
Sulphonylureas 1 (0.3) 60 (6.1)
Metformin + sulphonylureas 1 (0.3) 309 (31.4)
Others 10 (2.7) 188 (19.1)
Number of glucose-lowering drugs
1 37 (9.9) 379 (38.6)
2 6 (1.6) 344 (35)
>2 0 (0) 104 (10.6)
Insulin 375 (100) 343 (34.8)
ACEi/ARB 85 (22.7) 582 (59.2)
Antiplatelet agent 66 (17.6) 465 (47.3)
Statins 68 (18.1) 478 (48.6)
Hospital admissions* 30 (9.1) 40 (4.5)
Diabetes complications
Retinopathy 106 (28.3) 204 (20.7)
Neuropathy 65 (17.3) 200 (20.3)
Table 1 Characteristics of patients included (Continued)
Proteinuria¶ 89 (23.7) 190 (19.3)
Dialysis 16 (4.3) 43 (4.3)
Acute coronary syndrome 7 (1.8) 102 (10.4)
Heart failure 5 (1.3) 50 (5)
Stroke 4 (1) 42 (4.2)
Peripheral vascular disease 14 (3.7) 134 (13.6)
Plus – minus values are means ± standard deviations. Numbers in brackets
mean percentage of an absolute number. N number, yrs age in years, BMI
body mass index, ACEi angiotensin converting enzyme inhibitor, ARB
angiotensin receptor blocker.
*: related to the past 3 months of the visit.
¶: Proteinuria was defined as raised urine protein:creatinine ratio (>200 mg/g)
or urine albumin:creatinine ratio (>250 mg/g for men and >355 mg/g for
women) or total protein 24-hour excretion (>300 mg/day).
Table 2 Prevalence of cardiovascular risk factors
Diabetes
Type 1 (N=375) Type 2 (N=983)
Hypertension 84 (22.8) 729 (75.7)
Dyslipidemia 103 (28.5) 672 (70.9)
Smoking
Current 42 (11.4) 107 (11.3)
Previous 21 (5.7) 160 (16.9)
Never 305 (82.9) 678 (71.7)
Central obesity 146 (38.9) 822 (83.6)
Metabolic syndrome
NCEP - 562 (57.1)
IDF - 522 (53.1)
Numbers in brackets mean percentage of an absolute number.
NCEP National Cholesterol Education Program criteria, IDF International
Diabetes Federation criteria. Central obesity defined as waist circumference >90 cm
in men and >80 cm in women according to the IDF recommendations for
South Americans.
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in individuals with diabetes. Second, by using established
definitions for diabetes control and other cardiovascular
risk factors, we were able to put the Brazilian numbers in
perspective to the international literature and assess the
local practice. Third, the selection of investigators, al-
though not random, covered the main Brazilian regions,
providing a national picture of diabetes care.
The present study has several limitations. Diabetes mel-
litus types 1 and 2 are quite different conditions. Although
characterized by increased glycemic levels, it may be im-
proper to compare individuals with diseases quite distinct.
There was no standardization of laboratory results, as each
investigator used the locally available laboratory, although
no significant changes were expected in the results ob-
tained, had they been done in a central laboratory. As the
selection of investigators was based on ability and experi-
ence in the insulin therapy and layouts of high complexity,
this may have reflected in a greater representation in the
study sample of individuals with long-term evolution of
diabetes, greater difficulty of control, and therefore a higher
prevalence of complications in connection with the disease.
Although, the study protocol determined that investigators
were supposed to enroll consecutive patients, we cannot
disregard the possibility of selection bias.
Most patients included were private health care users
with high levels of education. Therefore, they do not repre-
sent the overall Brazilian population with DM. This limits
the generalizability of our findings. However it is possible
that for the average individual with DM in Brazil, the ac-
cess to less-experienced physicians, an inferior educational
level, and limited availability of diagnostic tests and more
advanced medications, results could be much worse than
those obtained in the present study.
The projections of DM for the next decades indicate
marked increase in cases of cases along with microvascu-
lar and macrovascular complications. Management of the
disease should attempt to modify different aspects of an
individual’s life, such as eating habits, physical activity
levels, correct use of multiple medications and insulin ad-
ministration, laboratory monitoring, and screening for
cardiovascular diseases.
There are consistent evidences that optimal glycemic
control, along with control of hypertension, dyslipidemia,
smoking cessation, and weight loss are necessary for redu-
cing cardiovascular risk in these patients. However, even in
a favourable environment in which patients with high edu-
cational level have access guaranteed by private insurance
to experienced physicians, only a small number achieve
proper metabolic control. Comparing it to international
reports, the Brazilian figures are poorer, with worse levels
of control of plasma glucose levels and associated cardio-
vascular risk factors.
We conclude that the BDMPS is relevant to disclose
the scenario of the DM control in an emerging country
like Brazil, and calls attention to the need of better edu-
cational strategies to try improve this picture.
Table 3 Proportion of individuals with adequate
metabolic control according to the levels of glycated
hemoglobin, blood pressure, lipids, waist circumference,
BMI, and smoking
Diabetes
Type 1
(N=375)
Type 2
(N=983)
Blood pressure <130/80 mm Hg 162 (43.3) 162 (16.7)
Glycated hemoglobin <7% 77 (22.1) 379 (43.2)
LDL-cholesterol <100 mg/dL 138 (36.8) 420 (42.7)
TGC <150 mg/dL 248 (66.1) 507 (51.5)
HDL-cholesterol (≥40 mg/dL, males)* 81 (77.9) 218 (56.0)
HDL-cholesterol (≥50 mg/dL, females)* 129 (75.0) 218 (47.4)
Waist circumference (<90 cm, males)* 98 (70) 76 (17.4)
Waist circumference (<80 cm, females)* 123 (54.2) 70 (13.2)
BMI <25 kg/m2 261 (69.2) 218 (22.1)
Non-smokers 305 (82.9) 678 (71.7)
Adequate control of at least 5 risk factors 134 (35.7) 142 (14.4)
Numbers in brackets mean percentage of an absolute number.
TGC tryglicerides, BMI body mass index.
* To calculate the proportion of individuals with normal waist circumference
and HDL-cholesterol among type 1 and 2 DM individuals according to sex, we
used the total number of females or males present in each group on
the denominator.
Table 4 Variables associated to an adequate metabolic control
Diabetes
Type 1 (N=241) Type 2 (N= 698)
OR 95% CI P value OR 95% CI P value
Female gender, (yes vs. no) 1.61 1.21-2.15 0.001 1.22 1.004-1.5 0.046
Age, per 1 year 0.99 0.97-1.02 0.581 1.02 1.001-1.04 0.04
Hypertension, (no vs. yes) 2.22 1.51-3.26 <.0001 1.48 1.19-1.85 0.0005
HDI, per 1 point 5.9 0.32-107.8 0.45 12.3 0.78-194.4 0.36
Higher education, (yes vs. no) 0.94 0.71-1.24 0.67 0.97 0.79-1.19 0.74
OR odds ratio, CI confidence interval, N number, HDI human development index.
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